Author

M. R. Savani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1 Assay:proteomics· 1

Frequent Co-Authors

D. D. Shi· 2 shared K. G. Abdullah· 2 shared L. C. Gattie· 2 shared L. G. Zacharias· 2 shared M. S. Martin-Sandoval· 2 shared M. S. Regan· 2 shared Q.-D. Nguyen· 2 shared R. J. DeBerardinis· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. D. Shi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Stable isotope tracing in human plasma-like medium reveals metabolic and immune modulation of the glioblastoma microenvironment

M. R. Savani, M. El Shami, L. C. Gattie, B. C. Smith, W. H. Hicks, S. S. Oken, L. G. Zacharias, M. S. Martin-Sandoval, E. Y. Montgomery, Y. Xiao, D. D. Shi, J. N. Rich, T. E. Richardson, P. O. Zinn, B. C. Lega, , K. G. Abdullah

This paper develops an in vitro method using human plasma-like medium to study glioma metabolism and immune interactions, revealing microenvironment-dependent metabolic features and immune responses.

bioRxiv · May 29, 2023Cancer Biology

De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma

D. D. Shi, M. R. Savani, M. M. Levitt, A. C. Wang, J. E. Endress, C. E. Bird, J. Buehler, S. A. Stopka, M. S. Regan, Y.-F. Lin, W. Gao, J. Khanal, M. Xu, B. Huang, R. B. Jennings, , McBray

This study identifies de novo pyrimidine synthesis as a therapeutic target in IDH mutant gliomas, showing that DHODH inhibitors are effective in preclinical models.

bioRxiv · Nov 30, 2021Cancer Biology

A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma

S. PAL, J. P. Kaplan, H. Nguyen, S. A. Stopka, M. R. Savani, M. S. Regan, Q.-D. Nguyen, K. L. Jones, L. A. Moreau, J. Peng, M. G. Dipiazza, A. Perciaccante, X. Zhu, B. Hunsel, K. X. Liu, , D. Haas-Kogan

This paper identifies a druggable metabolic vulnerability in diffuse midline glioma through a CRISPR screen, showing that inhibition of DHODH reduces pyrimidine biosynthesis and extends survival in mouse models.

bioRxiv · Nov 30, 2021Cancer Biology